JOM KITA KE POLITEKNIK

Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder (CIAO-II) (Record no. 2039)

MARC details
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Asherson, P
Relator term author
9 (RLIN) 1771
245 00 - TITLE STATEMENT
Title Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder (CIAO-II)
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2023-01.
500 ## - GENERAL NOTE
General note /pmc/articles/PMC7613969/
500 ## - GENERAL NOTE
General note /pubmed/35657651
520 ## - SUMMARY, ETC.
Summary, etc. BACKGROUND: 20-30% of prisoners meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD). Methylphenidate reduces ADHD symptoms but effects in prisoners are uncertain due to comorbid mental health and substance use disorders. AIM: To estimate the efficacy of an Osmotic-Release-Oral-System methylphenidate (OROS-methylphenidate) in reducing ADHD symptoms in young adult prisoners with ADHD. METHODS: An 8-week parallel arm, double-blind, randomised, placebo-controlled trial of OROS-methylphenidate versus placebo in male prisoners (aged 16-25) meeting DSM-5 criteria for ADHD. Primary outcome was ADHD symptoms at 8-weeks using the investigator rated Connors Adult ADHD Rating Scale (CAARS-O). Thirteen secondary outcome measures included emotional dysregulation, mind-wandering, violent attitudes, mental health symptoms, and prison officer and educational staff ratings of behaviour and aggression. FINDINGS: Mean CAARS-O at 8 weeks in the OROS-methylphenidate arm was estimated to be reduced by 0.57 points relative to the Placebo arm (95% CI: -2.41 to 3.56) and non-significant. The responder rate, defined as a 20% reduction in CAARS-O scores was 48.3% for the OROS-methylphenidate arm and 47.9% for the placebo arm. No statistically significant trial arm differences were detected for any of the secondary outcomes. Mean final titrated dose was 53.8 mg in the OROS-methylphenidate arm. CONCLUSIONS: ADHD symptoms did not respond to OROS-methylphenidate in young adult prisoners. The findings do not support routine treatment with OROS-methylphenidate in this population. Further research is needed to evaluate effects of higher average dosing and adherence to treatment, multimodal treatments, and preventative interventions in the community. TRIAL REGISTRATION: EudraCT Number 2015-004271-78; ISRCTN16827947. Database lock 27(th) August 2019
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction
546 ## - LANGUAGE NOTE
Language note en
690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN)
Topical term or geographic name as entry element Article
655 7# - INDEX TERM--GENRE/FORM
Genre/form data or focus term Text
Source of term local
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Johansson, L
Relator term author
9 (RLIN) 1772
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Holland, R
Relator term author
9 (RLIN) 1773
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Bedding, M
Relator term author
9 (RLIN) 1774
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Forrester, A
Relator term author
9 (RLIN) 1775
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Giannulli, L
Relator term author
9 (RLIN) 1776
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Ginsberg, Y
Relator term author
9 (RLIN) 1777
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Howitt, S
Relator term author
9 (RLIN) 1778
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Kretzschmar, I
Relator term author
9 (RLIN) 1779
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Lawrie, SM
Relator term author
9 (RLIN) 1780
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Marsh, C
Relator term author
9 (RLIN) 1781
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Kelly, C
Relator term author
9 (RLIN) 1782
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Mansfield, M
Relator term author
9 (RLIN) 1783
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name McCafferty, C
Relator term author
9 (RLIN) 1784
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Khan, K
Relator term author
9 (RLIN) 1785
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Muller-Sedgwick, U
Relator term author
9 (RLIN) 1786
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Strang, J
Relator term author
9 (RLIN) 1787
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Williamson, G
Relator term author
9 (RLIN) 1788
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Wilson, L
Relator term author
9 (RLIN) 1789
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Young, S
Relator term author
9 (RLIN) 1790
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Landau, S
Relator term author
9 (RLIN) 1791
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Thomson, L
Relator term author
9 (RLIN) 1792
786 0# - DATA SOURCE ENTRY
Note Br J Psychiatry
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="http://dx.doi.org/10.1192/bjp.2022.77">http://dx.doi.org/10.1192/bjp.2022.77</a>
Public note Connect to this object online.

No items available.